Increased Serum E-Selectin Levels Were Associated with Cognitive Decline in Patients with Stroke

Previous studies have reported that patients with stroke have a high incidence of cognitive decline. The aim was to elucidate the association between serum E-selectin levels and cognitive function in stroke patients.

Serum levels of E-selectin were measured in 322 patients with stroke at baseline. Cox proportional hazard analysis was used to evaluate the predictive value of serum E-selectin for predicting cognitive decline (end point) in patients with stroke.

Multivariate linear regression analysis revealed that serum E-selectin levels were independently associated with MOCA score after adjusting for age, gender, BMI, current smoker, current drinker, admission systolic and diastolic BP, CVD history and laboratory measurements in patients with stroke at baseline (Sβ= -0.156; 95% CI, - 0.170- - 0.074; P<0.001). The multivariate Cox proportional hazard analysis revealed that serum E-selectin (HR=2.481, 95% CI 1.533-4.327, P-trend <0.001) was an independent prognostic factor for cognitive decline in these patients with stroke during the follow-up period.

Our results showed that increased serum E-selectin levels were significantly and independently associated with cognitive decline and had independent predictive value for cognitive decline in patients with stroke. Serum E-selectin might enable early recognition of cognitive decline among stroke patients.